Equities

Sansure Biotech Inc

688289:SHH

Sansure Biotech Inc

Actions
Health CareMedical Equipment and Services
  • Price (CNY)22.96
  • Today's Change-0.61 / -2.59%
  • Shares traded6.92m
  • 1 Year change+27.70%
  • Beta--
Data delayed at least 15 minutes, as of Nov 14 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments4,7695,5644,681
Total Receivables, Net7331,396833
Total Inventory377355370
Prepaid expenses5811081
Other current assets, total121001.68
Total current assets5,9507,5255,966
Property, plant & equipment, net1,055793524
Goodwill, net7.66----
Intangibles, net3288446
Long term investments974657513
Note receivable - long term------
Other long term assets------
Total assets8,4549,1747,090
LIABILITIES
Accounts payable469791259
Accrued expenses228370177
Notes payable/short-term debt6900.01
Current portion long-term debt/capital leases11148.49
Other current liabilities, total143396220
Total current liabilities9191,572664
Total long term debt18146.41
Total debt982815
Deferred income tax591913
Minority interest2241212
Other liabilities, total325726
Total liabilities1,2531,673721
SHAREHOLDERS EQUITY
Common stock588588400
Additional paid-in capital1,9081,9142,065
Retained earnings (accumulated deficit)5,1775,3714,082
Treasury stock - common(515)(393)(200)
Unrealized gain (loss)453222
Other equity, total(1.78)(13)(0.02)
Total equity7,2017,5016,369
Total liabilities & shareholders' equity8,4549,1747,090
Total common shares outstanding572581587
Treasury shares - common primary issue167.385.34
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.